India Oligonucleotides Synthesis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

India Oligonucleotides Synthesis Market Size

• The India oligonucleotides synthesis market size was valued at USD 124.68 million in 2024 and is expected to reach USD 220.71 million by 2032, at a CAGR of 7.4% during the forecast period
• The market growth is largely fueled by increasing demand for advanced genetic research, personalized medicine, and expansion of the biotechnology sector in India, driving adoption of oligonucleotide synthesis solutions in both academic and commercial research settings
• Furthermore, the growing need for high-quality, custom oligonucleotides and the establishment of specialized service providers is positioning oligonucleotide synthesis as a critical component in genomics and therapeutics research, thereby significantly boosting the industry's growth

India Oligonucleotides Synthesis Market Analysis

• Oligonucleotide synthesis, providing custom DNA and RNA sequences for research, diagnostics, and therapeutics, is becoming an essential component of biotechnology and genomics research in India due to its critical role in genetic analysis, personalized medicine, and therapeutic development
• The growing demand for oligonucleotide synthesis is primarily driven by the expansion of biotechnology research, increasing government and private investments in genomics, rising prevalence of genetic disorders, and the need for precision medicine and novel therapeutics
• The market in India is supported by well-established research institutions, advanced biotechnology infrastructure, and the presence of leading service providers catering to both domestic and international clients
• The increasing adoption of automated and high-throughput synthesis technologies is enhancing efficiency, reducing production costs, and enabling faster delivery of oligonucleotides to meet growing research demands
• Custom Oligos segment dominated the India oligonucleotides synthesis market with a market share of 65.5% in 2024, driven by its high demand in personalized research, targeted therapeutics, and specialized diagnostic applications requiring tailored DNA and RNA sequences

Report Scope and India Oligonucleotides Synthesis Market Segmentation   

India Oligonucleotides Synthesis Market Trends

Rising Adoption of Advanced Genomics and Personalized Medicine

• A key and accelerating trend in the India oligonucleotides synthesis market is the increasing application of oligonucleotides in genomics research, personalized medicine, and gene-targeted therapeutics. This shift is enabling highly precise research and tailored treatment approaches
  • For instance, Indian biotech firms such as Syngene International and Strand Life Sciences are leveraging custom oligonucleotides to develop targeted therapeutics and molecular diagnostic assays, supporting both domestic and global research initiatives
• Oligonucleotide technologies are also being integrated into diagnostic platforms, enabling rapid detection of genetic disorders and infectious diseases. Advanced synthesis methods allow researchers to design sequences for specific mutations or targets, improving accuracy and efficiency in research and clinical applications
• The growing focus on high-throughput and automated oligonucleotide synthesis is enabling faster turnaround times and reducing costs for custom sequences, thereby increasing accessibility for academic and commercial research institutions
• This trend toward precise, automated, and scalable synthesis solutions is reshaping research and therapeutic development expectations, prompting companies such as MilliporeSigma and GeneProof India to expand their service offerings and enhance R&D capabilities
• Demand for oligonucleotides in applications such as diagnostics, therapeutics, and research is rising rapidly as Indian institutions prioritize innovation in genomics and personalized healthcare

India Oligonucleotides Synthesis Market Dynamics

Driver

Growing Demand Due to Expansion of Biotechnology Research and Precision Medicine

• The increasing investments in biotechnology research, coupled with the rising focus on precision medicine and genetic diagnostics, is a significant driver for the growing demand for oligonucleotide synthesis in India
  • For instance, in 2024, Strand Life Sciences expanded its custom oligonucleotide services to support precision oncology and molecular diagnostics, reflecting growing market opportunities for specialized synthesis solutions
• As Indian pharmaceutical and biotechnology companies focus on gene-targeted therapeutics and molecular diagnostics, oligonucleotides offer a critical tool for research and product development
• Furthermore, the rising prevalence of genetic disorders and infectious diseases is driving the adoption of oligonucleotide-based diagnostic and therapeutic solutions across academic and clinical research centers
• The availability of high-quality, custom oligonucleotides, combined with automation and high-throughput synthesis technologies, is enhancing research efficiency and enabling faster development cycles, thereby propelling market growth
• The growing collaborations between Indian biotech firms, academic institutions, and global pharmaceutical companies are further fueling market expansion by facilitating innovation, access to advanced synthesis techniques, and broader application of oligonucleotides in therapeutics and diagnostics

Restraint/Challenge

High Costs and Regulatory Compliance Hurdles

• The relatively high cost of custom oligonucleotide synthesis and advanced equipment poses a significant challenge for widespread adoption, particularly among smaller research institutions and startups in India. Premium synthesis services, high-quality reagents, and specialized instruments can limit accessibility for budget-conscious users
  • For instance, emerging biotech labs may face budget constraints in procuring high-throughput synthesizers or outsourcing custom oligonucleotide orders from established service providers
• Strict regulatory requirements for oligonucleotide production, especially for therapeutic applications, including compliance with Good Manufacturing Practices (GMP) and biosafety standards, add complexity and increase operational costs for companies
• Furthermore, variations in regulatory approvals for diagnostics and therapeutic applications across states can slow market entry and product adoption, affecting both domestic manufacturers and international collaborators
• Overcoming these challenges through cost optimization, investment in local synthesis infrastructure, and streamlined regulatory compliance processes will be essential for enabling broader adoption and sustained growth in the India oligonucleotide synthesis market

India Oligonucleotides Synthesis Market Scope

The market is segmented on the basis of type, product type, synthesis method, application, end user, and distribution channel.

• By Type

On the basis of type, the India oligonucleotides synthesis market is segmented into custom oligos and predesigned oligos. The custom oligos segment dominated the market with the largest revenue share of 65.5% in 2024, driven by its high demand in personalized research, targeted therapeutics, and specialized diagnostic applications requiring tailored DNA and RNA sequences. Pharmaceutical and biotechnology companies rely on custom oligos for gene therapy, molecular diagnostics, and therapeutic development. Academic and research institutes prefer custom sequences for experimental flexibility and high specificity in genomics studies. The segment benefits from fast turnaround times, high-quality synthesis, and expanding applications in precision medicine. Increasing adoption of high-throughput automated synthesis technologies further strengthens the dominance of this segment.

The predesigned oligos segment is expected to witness the fastest growth over the forecast period due to its cost-effectiveness and wide use in routine laboratory research, standard diagnostics, and educational applications. Predesigned oligos simplify workflows, reduce synthesis time, and are suitable for high-volume, repetitive experiments. Academic institutions, teaching labs, and small-scale diagnostic centers increasingly adopt predesigned sequences for rapid deployment. The growth is also fueled by increasing availability from local and international suppliers. This segment provides researchers with ready-to-use oligos, eliminating the need for custom synthesis for common sequences.

• By Product Type

On the basis of product type, the India oligonucleotides synthesis market is segmented into equipment, reagents, and consumables & accessories. The reagents & consumables segment dominated the market in 2024, accounting for 55% share, as these are critical for oligonucleotide synthesis workflows. Reagents, including phosphoramidites, buffers, and solvents, are consumed continuously, driving recurring demand. Consumables such as columns, plates, and filters support consistent quality and high yields. Pharmaceutical, biotech, and academic sectors contribute significantly to the segment’s revenue through routine usage. High demand is also driven by expanding research activities and increased adoption of PCR, NGS, and other molecular techniques. Service providers offering reagent kits with standardized quality further enhance market dominance.

The equipment segment is expected to witness the fastest growth during forecast period, driven by the adoption of automated and high-throughput synthesizers that improve efficiency, reproducibility, and reduce human error. Growing R&D activities in genomics, diagnostics, and therapeutics are prompting investments in advanced synthesis platforms. Indian research labs are increasingly replacing manual synthesis workflows with automated instruments. Compact, cost-effective, and high-precision synthesizers designed for Indian laboratories are gaining traction. Equipment innovation, including robotics and integrated software, is accelerating market adoption. Startups and CROs investing in in-house synthesis infrastructure are further boosting segment growth.

• By Synthesis Method

On the basis of synthesis method, the India oligonucleotides synthesis market is segmented into solid phase oligo synthesis and liquid/enzymatic phase oligo synthesis. The solid phase oligo synthesis segment dominated in 2024 due to its efficiency, scalability, and suitability for producing long and complex sequences. This method ensures high reproducibility and is compatible with automation, making it the preferred choice for pharmaceutical and biotech applications. It is widely adopted for therapeutic oligos and high-precision custom sequences. Research institutions value solid-phase methods for consistent quality and high yield. The segment is also strengthened by established infrastructure and trained personnel familiar with this synthesis technology. Overall, the method’s reliability, robustness, and broad application base reinforce its dominant market position.

The liquid/enzymatic phase synthesis segment is expected to register the fastest growth during forecast period, propelled by its potential in enzymatic DNA/RNA synthesis, greener production methods, and emerging applications in synthetic biology. Advancements in enzymatic methods allow faster, environmentally friendly, and cost-effective synthesis. This method is particularly attractive for startups and research labs exploring innovative therapeutics and diagnostics. Liquid-phase synthesis can produce sequences difficult for solid-phase methods. Adoption is rising due to increasing interest in automated enzymatic platforms. Growing awareness of sustainable laboratory practices also supports segment expansion.

• By Application

On the basis of application, the India oligonucleotides synthesis market is segmented into diagnostics, therapeutics, research, agriculture, food, and others. The diagnostics segment dominated the market with around 40% revenue share in 2024, due to increasing use of oligonucleotides in molecular diagnostics, genetic testing, and infectious disease detection. Rising prevalence of genetic disorders and demand for rapid, accurate diagnostic tools drive the segment. Clinical labs, hospitals, and diagnostic centers are major consumers, leveraging oligos for assay development and validation. Adoption of PCR, qPCR, and NGS-based tests further strengthens market dominance. Regulatory support for molecular diagnostics in India also contributes to segment growth. Continuous innovation in assay design ensures sustained demand for diagnostic oligos.

The therapeutics segment is expected to witness the fastest growth during forecast period, driven by expanding applications in RNA-based therapeutics, antisense oligonucleotides, and gene therapy. Pharmaceutical companies are increasingly investing in oligonucleotide therapeutics development. Growth is supported by collaborations with academic institutions and research labs. Increasing incidence of chronic and genetic diseases creates a rising need for precision therapeutics. Rapid technological advancements in oligonucleotide modifications enhance efficacy and safety, driving adoption. Government initiatives supporting biotechnology R&D also accelerate market expansion.

• By End User

On the basis of end user, the India oligonucleotides synthesis market is segmented into pharmaceutical & biotechnology companies, diagnostic centers, CROs, research & academic institutes, and forensic labs. The pharmaceutical & biotechnology companies segment dominated the market with the largest revenue share of 45% in 2024, due to high consumption of oligonucleotides for drug development, molecular diagnostics, and therapeutic research. The dominance is supported by strategic partnerships with academic institutions and contract service providers. Rising investment in gene-targeted therapies and precision medicine further boosts demand. The segment benefits from continuous adoption of high-throughput synthesis and custom oligo solutions. Large companies’ ability to place bulk orders ensures steady revenue contribution. The segment also benefits from access to international collaborations and technology transfer.

The research & academic institutes segment is expected to witness the fastest growth during forecast period, driven by increasing genomics and molecular biology research in India. Government funding for biotechnology and life sciences research is rising. Academic labs are adopting oligonucleotide synthesis for diverse applications such as gene function studies, biomarker discovery, and synthetic biology. Startups associated with universities are leveraging these services for innovative therapeutics and diagnostics. Increasing focus on personalized medicine and genetic studies accelerates adoption. Growing availability of automated synthesis and cost-effective solutions further supports segment expansion.

• By Distribution Channel

On the basis of distribution channel, the India oligonucleotides synthesis market is segmented into direct tender, retail sales, and others. The direct tender segment dominated the market in 2024, particularly for bulk purchases by pharmaceutical companies, biotech firms, and large research institutions, ensuring steady revenue streams. Direct contracts allow buyers to access custom synthesis services with bulk pricing and guaranteed delivery timelines. The segment benefits from established relationships between manufacturers and large end users. Repeat orders for reagents and custom oligos also strengthen revenue contribution. Bulk procurement ensures cost efficiency for buyers and stable demand for suppliers. The segment’s dominance is supported by the consistent growth of large-scale R&D and therapeutic development projects.

The retail sales segment is expected to witness the fastest growth during forecast period, as smaller research labs, startups, and educational institutions increasingly prefer flexible, on-demand ordering of reagents, consumables, and small-scale oligonucleotide batches. Online platforms and specialized distributors enhance accessibility and convenience. Smaller labs benefit from reduced upfront costs and fast delivery. Growth is fueled by the increasing number of academic programs and biotech incubators in India. Retail channels also enable access to international suppliers for specialized products. Flexibility and convenience make retail sales attractive for emerging users and pilot-scale research.

India Oligonucleotides Synthesis Market Share

The India oligonucleotides synthesis industry is primarily led by well-established companies, including:

• BioServe Biotechnologies (India)
• Synoligo Biotechnologies, Inc (India)
• Eurofins Genomics (India)
• Thermo Fisher Scientific Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Merck KGaA (Germany)
• Danaher Corporation (U.S.)
• LGC Limited (U.K.)
• General Electric Company (U.S.)
• Mettler Toledo (Switzerland)
• TriLink BioTechnologies (U.S.)
• Ajinomoto Bio-Pharma (Japan)
• Integrated DNA Technologies (U.S.)
• Kaneka Eurogentec (Belgium)
• LGC Biosearch Technologies (U.K.)
• Microsynth (Switzerland)
• MilliporeSigma (U.S.)
• BioSpring (Germany)
• Barcode Biosciences Private Limited. (India)

What are the Recent Developments in India Oligonucleotides Synthesis Market?

• In August 2025, Cohance Lifesciences announces cGMP Oligonucleotide facility in Hyderabad. Cohance Lifesciences, an Indian pharmaceutical company, announced an investment of Rs 230 million for a new cGMP (current Good Manufacturing Practice) oligonucleotide building block manufacturing facility in Hyderabad. This strategic investment aims to strengthen the company's integrated oligonucleotide platform and allow them to scale up high-value chemistries from a laboratory to full commercial manufacturing
• In December 2024, Co-Dx and CoSara inaugurate an oligo synthesis facility in Ranoli, India. Co-Dx, a U.S.-based diagnostics company, and its Indian joint venture, CoSara Diagnostics Pvt. Ltd., inaugurated an oligonucleotide synthesis facility in Ranoli, Gujarat. The facility is designed to support the "Make in India" initiative and will be used to manufacture their patented Co-Primers chemistry, which is a key component of their lab-based PCR tests
• In November 2023, Twist Bioscience launched its new Twist Express Genes service, designed to offer custom gene synthesis with a rapid turnaround time of five to seven business days. This development is significant for the Indian market as it improves the accessibility of custom gene synthesis services for researchers and biotech companies, accelerating their R&D activities
• In June 2021, Twist Bioscience announced the acquisition of iGenomX, a company specializing in multiplex library preparation tools for next-generation sequencing (NGS). This acquisition expanded Twist's capabilities and product portfolio in the NGS market. This development is relevant to India as it enhances the availability of advanced tools for genomics research and diagnostics, both of which are major application areas for oligonucleotides in the country
• January 2021, Merck, a leading science and technology company with a strong presence in India, announced the acquisition of AmpTec, a German-based mRNA contract development and manufacturing organization (CDMO). This strategic acquisition bolsters Merck's expertise in the rapidly growing field of mRNA technology, which is a major driver for the oligonucleotide synthesis market. For the Indian market, this means enhanced access to technologies and services related to mRNA-based vaccines and therapeutics

SKU-70222